Skip to main content

Sayana Press (DMPA-SC in Uniject) Clinical Brief

Sayana® Press is a new formulation and presentation of the injectable contraceptive Depo-Provera®, manufactured and patented by Pfizer Inc. Administered through subcutaneous injection, Sayana Press contains 30% less depot medroxyprogesterone acetate (DMPA) than the intramuscular presentation of Depo-Provera (generic: DMPA-IM). Studies have found that the contraceptive efficacy and safety profile of Sayana Press (DMPA-SC in the Uniject™ injection system) are equivalent to those of DMPA-IM. Sayana Press is indicated for the prevention of pregnancy in women of childbearing potential. Sayana Press is presented in the Uniject injection system, an autodisable injection device, prefilled with 104 mg/0.65 mL* medroxyprogesterone acetate (MPA, the active ingredient, a synthetic form of the natural hormone progesterone) sterile aqueous suspension. In addition to providing three months of effective contraception, Sayana Press shares other characteristics of DMPA-IM, including: Rapid onset of effect: No backup contraceptive method is required during the first cycle of use; High efficacy: It is not compromised by body mass index (BMI); Convenient administration: It is easy to use; Discreet administration: Women can use it without telling their partners or families; Safety: It can be used by women for whom contraceptive use of estrogen is inappropriate or contraindicated.

Institutional Author(s): PATH
Publication date: March, 2017

  • Brief Link to Website